These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22161157)

  • 1. Weapons ovarian epithelial tumors may use in immune escape: an immunohistochemical correlational study.
    Hasby EA
    Pathol Oncol Res; 2012 Apr; 18(2):509-18. PubMed ID: 22161157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors.
    Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tokuda M
    Int J Oncol; 2002 Aug; 21(2):315-20. PubMed ID: 12118327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survivin in ovary tumors.
    Plewka D; Jakubiec-Bartnik B; Morek M; Bogunia E; Bienioszek M; Wolski H; Kotrych D; Dziekan K; Seremak-Mrozikiewicz A; Plewka A
    Ginekol Pol; 2015 Jul; 86(7):525-30. PubMed ID: 26376531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
    Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
    Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinicopathological significance of Bax and Bcl-2 protein expression with tumor infiltrating lymphocytes in ovarian carcinoma.
    Yigit S; Demir L; Tarhan MO; Cabuk FK; Ellidokuz H; Erten C; Somali I; Dirican A; Cakalagaoglu F
    Neoplasma; 2012; 59(5):475-85. PubMed ID: 22668011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Fas and FasL in human serous ovarian epithelial tumors.
    van Haaften-Day C; Russell P; Davies S; King NJ; Tattersall MH
    Hum Pathol; 2003 Jan; 34(1):74-9. PubMed ID: 12605369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.
    Byrne JA; Maleki S; Hardy JR; Gloss BS; Murali R; Scurry JP; Fanayan S; Emmanuel C; Hacker NF; Sutherland RL; Defazio A; O'Brien PM
    BMC Cancer; 2010 Sep; 10():497. PubMed ID: 20846453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD105/Ki67 coexpression correlates with tumor progression and poor prognosis in epithelial ovarian cancer.
    Liu P; Sun YL; Du J; Hou XS; Meng H
    Int J Gynecol Cancer; 2012 May; 22(4):586-92. PubMed ID: 22266931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy.
    Tsiatas ML; Gyftaki R; Liacos C; Politi E; Rodolakis A; Dimopoulos MA; Bamias A
    Int J Gynecol Cancer; 2009 Nov; 19(8):1329-34. PubMed ID: 20009885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B7-H4 overexpression in ovarian tumors.
    Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
    Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of survivin in ovarian epithelial carcinoma and its correlation with expression of Fas and FasL].
    Ma XY; He FX; Wu SF; Lu YP; Ma D
    Ai Zheng; 2004 Feb; 23(2):173-6. PubMed ID: 14960238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer.
    Bösmüller HC; Wagner P; Peper JK; Schuster H; Pham DL; Greif K; Beschorner C; Rammensee HG; Stevanović S; Fend F; Staebler A
    Int J Gynecol Cancer; 2016 May; 26(4):671-9. PubMed ID: 26905331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed Death Ligand 1 (PD-L1) Expression in Epithelial Ovarian Cancer: A Comparison of Type I and Type II Tumors.
    Nhokaew W; Kleebkaow P; Chaisuriya N; Kietpeerakool C
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1161-1169. PubMed ID: 31030490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lost expression of DCC gene in ovarian cancer and its inhibition in ovarian cancer cells.
    Meimei L; Peiling L; Baoxin L; Changmin L; Rujin Z; Chunjie H
    Med Oncol; 2011 Mar; 28(1):282-9. PubMed ID: 20054719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome in serous ovarian cancer is not associated with LATS expression.
    Montavon C; Stricker GR; Schoetzau A; Heinzelmann-Schwarz V; Jacob F; Fedier A
    J Cancer Res Clin Oncol; 2019 Nov; 145(11):2737-2749. PubMed ID: 31586262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of hypoxia inducible factors on the immune microenvironment in ovarian cancer.
    Duechler M; Peczek L; Szubert M; Suzin J
    Anticancer Res; 2014 Jun; 34(6):2811-9. PubMed ID: 24922644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alteration of BRCA-1 tumor suppressor gene expression in serous and mucinous ovarian neoplasms in the benign-borderline-malignant pathway.
    Yousif HMA; Mohammed RAA
    Curr Probl Cancer; 2019 Aug; 43(4):377-385. PubMed ID: 30446260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis.
    Fang Y; Li Z; Wang X; Zhang S
    Tumour Biol; 2012 Dec; 33(6):2299-306. PubMed ID: 22923389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer.
    Leffers N; Vermeij R; Hoogeboom BN; Schulze UR; Wolf R; Hamming IE; van der Zee AG; Melief KJ; van der Burg SH; Daemen T; Nijman HW
    Int J Cancer; 2012 Jan; 130(1):105-12. PubMed ID: 21328579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survivin and cycline D1 expressions are associated with malignant potential in mucinous ovarian neoplasms.
    Kanter M; Turan G; Usta C; Usta A; Esen HH; Tavlı L; Celik C; Demirkol Y; Kanter B
    J Mol Histol; 2016 Apr; 47(2):145-52. PubMed ID: 26815661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.